Associated Papers
Mutational landscape of primary, metastatic, and recurrent ovarian cancer reveals c-MYC gains as potential target for BET inhibitors.
Li C et al.
Proceedings of the National Academy of Sciences of the United States of America, 2019
Functional consequences of the first reported mutations of the proto-oncogene PTTG1IP/PBF.
Imruetaicharoenchoke W et al.
Endocrine-related Cancer, 2017
Select a paper to view details